Clinicopathological Significance of Plasminogen Activator Inhibitor-1 Promoter 4G/5G Polymorphism in Breast Cancer: A Meta-analysis

Archives of Medical Research

Volumn 44, Issue 1, 2013, Pages 39-45

  Lee, Ju Han ^a   Kim, Younghye ^a   Choi, Jung Woo ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

Breast cancer; Meta analysis; PAI 1; Polymorphism

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; DNA POLYMORPHISM; EFFECT SIZE; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PROMOTER REGION;

BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; ODDS RATIO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC;

EID: 84873181247     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.12.002     Document Type: Article

References (34)

1. Schmitt M., Janicke F., Moniwa N., et al. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 1992, 373:611-622.
2. Durand M.K., Bodker J.S., Christensen A., et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004, 91:438-449.
3. Stefansson S., McMahon G.A., Petitclerc E., et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003, 9:1545-1564.
4. Berger D.H. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002, 26:767-771.
5. Castello R., Espana F., Vazquez C., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res 2006, 117:487-492.
6. Choi J.W., Lee J.H., Park H.S., et al. PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma. J Clin Pathol 2011, 64:893-897.
7. Harbeck N., Kates R.E., Gauger K., et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004, 91:450-456.
8. Palmirotta R., Ferroni P., Savonarola A., et al. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009, 124:403-408.
9. Sternlicht M.D., Dunning A.M., Moore D.H., et al. Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiol Biomarkers Prev 2006, 15:2107-2114.
10. Bajou K., Masson V., Gerard R.D., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001, 152:777-784.
11. Czekay R.P., Aertgeerts K., Curriden S.A., et al. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003, 160:781-791.
12. Webb D.J., Thomas K.S., Gonias S.L. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001, 152:741-752.
13. Chen Y.Q., Sloan-Lancaster J., Berg D.T., et al. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost 2001, 86:1563-1572.
14. Dong J., Fujii S., Li H., et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-delta. Arterioscler Thromb Vasc Biol 2005, 25:1078-1084.
15. Ha H., Oh E.Y., Lee H.B. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009, 5:203-211.
16. Swiatkowska M., Szemraj J., Cierniewski C.S. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J 2005, 272:5821-5831.
17. Grancha S., Estelles A., Tormo G., et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1999, 81:516-521.
18. Burzotta F., Di Castelnuovo A., Amore C., et al. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction. Thromb Haemost 1998, 79:354-358.
19. Eriksson P., Kallin B., van't Hooft F.M., et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995, 92:1851-1855.
20. Nordt T.K., Lohrmann J., Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res 2001, 103(Suppl 1):S1-S5.
21. Alvarez-Millan J.J., Bocos C., Ferrin V., et al. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells. Oncology 2002, 62:286-290.
22. Blasiak J., Smolarz B. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochim Pol 2000, 47:191-199.
23. Eroglu A., Ulu A., Cam R., et al. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer. J BUON 2006, 11:481-484.
24. Lei H., Hemminki K., Johansson R., et al. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer. Breast Cancer Res Treat 2008, 109:165-175.
25. Minisini A.M., Fabbro D., Di Loreto C., et al. Markers of the uPA system and common prognostic factors in breast cancer. Am J Clin Pathol 2007, 128:112-117.
26. Yagmurdur M.C., Atac F.B., Tutar N.U., et al. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast. Int Surg 2008, 93:163-168.
27. Zhang X., Shu X.O., Cai Q., et al. Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival. Clin Cancer Res 2006, 12:6037-6042.
28. Lee J.H., Lee E.S., Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110:38-46.
29. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999, 18:321-359.
30. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
31. Chong N.W., Codd V., Chan D., et al. Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett 2006, 580:4469-4472.
32. Dimova E.Y., Kietzmann T. The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2. Ann NY Acad Sci 2006, 1090:355-367.
33. Ma Z., Jhun B., Jung S.Y., et al. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol 2008, 121:1006-1012.e1002.
34. Iwaki T., Urano T., Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012, 157:291-298.